On August 26, 2022, the U.S. Food and Drug Administration approved pemigatinib (Pemazyre®) for adults with relapsed or refractory myeloid or lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.
On August 29, 2022, the U.S. Food and Drug Administration reported Intera Oncology’s recall of the Intera 3000 hepatic artery infusion pump because of reports that the devices were delivering medications faster than expected. FDA identified it as a class I recall, the most serious type of recall, where use of the device may cause serious injuries or death.
A person’s zip code often matters more than their genetic code when it comes to their health. Where we live and work, how connected we are in our community, and how much support we have are core social determinants of health that also significantly affect cancer health outcomes.
To improve cancer care and lower costs, the Centers for Medicare and Medicaid Services created the Enhancing Oncology Model in June 2022.
PITTSBURGH, PA—August 25, 2022—Seven emerging Oncology Nursing Society member leaders under age 40, representing diverse oncology nursing backgrounds around the world, joined the ONS Leadership Development Committee’s 2022 Young Leaders pilot program.
On August 24, 2022, the U.S. Food and Drug Administration approved ibrutinib (Imbruvica®) for pediatric patients aged less than 1 year with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
Vision boards are a collage of images and phrases that represent your goals, dreams, and attitudes; they help you manifest your aspirations by physically placing your thoughts into the world. Although few studies have measured their effectiveness, experts suggest that creating a vision board can help you reach your goals.
With broad backgrounds in oncology genetics, immunology, and disparities, President Joe Biden’s three July 2022 appointments to the Cancer Cabinet will help guide the United States on opportunities to reduce cancer’s barriers and burden for underserved populations.
A compound the body produces when fasting or following a ketogenic diet may slow or stop the growth of colorectal cancer (CRC) cells, according to study results published in Nature.
When OpdualagTM (nivolumab and relatlimab-rmbw), a fixed-dose combination therapy that consists of two distinct monoclonal antibodies, received FDA approval on March 18, 2022, for the treatment of unresectable or metastatic melanoma for adult and pediatric patients 12 years of age or older, it became the first approved combination therapy that includes two distinct immunotherapy agents in a single infusion. Relatlimab-rmbw is also the first approved lymphocyte activation gene-3–blocking antibody.